Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

VOSEVI

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

Standard Dose
400MG;100MG;100MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview VOSEVI is listed in Drugs@FDA under application 209195 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR Form and strength TABLET;ORAL - 400MG;100MG;100MG Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2019-11-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview VOSEVI is listed in Drugs@FDA under application 209195 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR Form and strength TABLET;ORAL - 400MG;100MG;100MG Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2019-11-15 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
VOSEVI (SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR) | Drug Monograph | MedicHelpline